Samples to determine HCV RNA levels were collected from patients at screening; baseline/Day 1 (predose); Weeks 2, 4, 8, and 12 (or upon early termination); and posttreatment Weeks 4 and 12. The COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0 was used to quantify HCV RNA in this study. The lower limit of quantitation of this assay is 15 IU/ml. The primary efficacy endpoint was the proportion of patients with SVR12, defined as HCV RNA less than the lower limit of quantitation (<15 IU/mL) 12 weeks after cessation of treatment.
Secondary efficacy endpoints included the proportion of patients with sustained virologic response at posttreatment week 4 (SVR4), the proportion of patients with HCV RNA less than the lower limit of quantitation while on treatment, HCV RNA (log 10 IU/mL) and changes from baseline in HCV RNA (log 10 IU/mL) through the end of treatment, and the proportion of patients with virologic failure.
For efficacy endpoints, the 2-sided 95% exact confidence interval (CI) was calculated for the percentages of patients with SVR12, SVR4 and HCV RNA below the lower limit of quantitation at each post-baseline visit using the Clopper-Pearson method. Summary statistics were calculated for absolute values and changes from baseline in HCV RNA (log 10 IU/mL) by visit through the end of treatment. No statistical comparisons were conducted.
Baseline deep sequencing analysis was performed for all patients (15% assay cut-off). The HCV NS3, NS5A and NS5B coding regions were amplified using standard reverse transcriptase-polymerase chain reaction (RT-PCR) technology. Following amplification, RT-PCR products were deep sequenced.
| RE SULTS
Of the 38 patients screened for the study, 31 patients were enrolled. The 7 patients not enrolled did not meet all inclusion and exclusion criteria (3 patients had cirrhosis but did not have liver imaging within 6 months to exclude hepatocellular carcinoma, 4 patients had exclusionary medical history or were not in general good health, 2 patients had laboratory parameters outside acceptable ranges, 1 patient had clinically relevant alcohol or drug abuse within 12 months prior to screening and 1 patient had not received a prior HCV treatment regimen required for enrolment). The 31 patients enrolled had HCV genotype 1a (48%), 1b (13%), 2 (7%), 3 (26%), 4 (3%) or 5 (3%), and approximately half (48%) had cirrhosis. All patients had previously experienced virologic relapse after completing a SOF-and VEL-containing regimen ( Figure 1A ). Seventeen patients (55%) had previously received SOF/VEL/VOX for 8 weeks, all of whom had been treated in Study GS-US-342-1172 (POLARIS-2). 4 Eleven patients (35%) had pre- 
| D ISCUSS I ON
SOF/VEL for 12 weeks has demonstrated high efficacy in clinical trial and real-world settings [8] [9] [10] and is a recommended first-line regimen for DAA-naïve patients regardless of genotype or cirrhosis status. 1, 2 In Europe and in other regions, SOF/VEL/VOX for 8 weeks is available for use in DAA-naïve patients without cirrhosis.
In the POLARIS-2 and POLARIS-3 studies, few patients who failed treatment with 8 weeks of SOF/VEL/VOX had treatment-emergent RASs (1 of 23 virologic failures), 4 suggesting that retreatment with the same regimen for a longer duration may be successful.
A 12-week course of SOF/VEL/VOX is an approved salvage regimen for NS5A inhibitor-experienced patients, but due to the timing of the POLARIS-1 study, limited data existed for patients who had failed a SOF-and VEL-containing regimen. In this study, treatment with SOF/ VEL/VOX for 12 weeks resulted in an SVR12 rate of 100% (31 of 31 patients; 95% CI: 89% to 100%) in patients with chronic HCV infection who did not achieve a sustained virologic response with prior exposure to SOF and VEL. Most patients had received prior treatment with SOF/ VEL/VOX for 8 weeks (55%) or SOF/VEL for 12 weeks (35%).
Treatment with SOF/VEL/VOX for 12 weeks was well tolerated in this study. Adverse events were reported in 61% of patients, and most were Grade 1 or 2 in severity. The only adverse events reported for more than 10% of patients were fatigue or nausea (each 16%), and headache (13%). Of note, in previous studies of SOF/VEL/ VOX, 3 diarrhoea was reported in 19% of patients receiving 12 weeks of SOF/VEL/VOX. However, in the current study, diarrhoea was reported in only 7% of patients.
Overall, these results demonstrate the contribution of both the addition of the protease inhibitor VOX to the potent nucleotide/NS5A inhibitor combination of SOF/VEL, and the longer treatment period with SOF/VEL/VOX for retreatment of both noncirrhotic and cirrhotic patients who had been previously treated with SOF/VEL for 12 weeks or SOF/VEL/VOX for 8 weeks. The results also further support the use of SOF/VEL/VOX for 12 weeks as a salvage regimen for patients who have failed prior therapy with NS5A inhibitor-containing regimens.
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